Looking for a specific product?

Make a search for products & suppliers, articles & news.

Promising Ebola vaccine

Preliminary results from the Norwegian-led trial underway in Guinea, published in the UK medical journal The Lancet, indicate that the vaccine may provide complete protection against Ebola virus disease.

The vaccine study is a collaboration between the public health authorities in Guinea, the World Health Organization (WHO), Doctors Without Borders/Epicentre and the Norwegian Institute of Public Health. The pilot phase of the trial began in late March 2015 and thus far the study has recruited roughly 4 000 trial participants.

“I believe this could be the first effective Ebola vaccine ever developed,” says John-Arne Røttingen of the Norwegian Institute of Public Health. John-Arne Røttingen, Director of the Division of Infectious Disease Control at the Norwegian Institute of Public Health and head of the study’s steering committee, says, “The initial results give us reason to believe this could be the world’s first effective Ebola vaccine ever developed.”

GLOBVAC programme very pleased

“We are very pleased that the results thus far are so encouraging,” says Programme Coordinator of the GLOBVAC programme Åse-Marit Kristiansen. “An effective Ebola vaccine would save many lives.”

“This is a prime example of the importance of strong initiatives in the field of global health and vaccination research as well as of international cooperation in this field,” she adds.

Vaccinating in a ring

The trial employs a “ring vaccination” design that vaccinates a ring of people around new Ebola cases, typically around and including the village or neighbourhood in which the infected person lives.

A randomly selected half of these rings were given the vaccine immediately, while the other half of the rings received the vaccine 21 days later.

The number of infected cases among those immediately vaccinated was then compared to the number of cases identified in the group with delayed vaccination. This enabled researchers to measure the protective effect of the vaccine, while at the same time ensuring that all participants were offered the vaccine, as required under the trial.

Ring vaccination was employed in the campaign to eradicate smallpox in the 1970s but has never before been used in clinical trials.

“Here we clearly see the importance of strong research initiatives in the field of global health and vaccination research,” says Programme Coordinator of the GLOBVAC programme Åse-Marit Kristiansen. Immediate vaccination may give full protection

“None of the participants who received immediate vaccination have become ill so far,” says Dr Røttingen. This could indicate that the vaccine provides complete protection against Ebola. In the control group, by contrast, where participants received the vaccine 21 days later, there were several Ebola cases.

In light of these promising results, an independent committee in charge of monitoring participant safety and the trial outcomes has concluded that it is unethical to continue delaying vaccination. The committee thus recommends that the trial offer vaccines immediately to all those in contact with Ebola-infected people.

“From a strictly scientific point of view we would want more solid data,” explains Dr Røttingen, “but from a public health perspective as well as for ethical reasons we in the steering committee along with WHO have decided to proceed with immediate vaccination of all rings and to publish the interim results.”

Guinea badly affected

Guinea is one of the West African countries most severely affected by the Ebola epidemic. As of the beginning of July 2015 over 11 000 people have died from the disease in West Africa, some 2 500 of them in Guinea.

The continuation of the trial could help to control the still ongoing outbreak in Guinea, and ring vaccination could be relevant for new cases in Sierra Leone as well.

The trial is being funded by the Norwegian Ministry of Foreign Affairs through allocations via the Research Council, as well as by the Wellcome Trust and the Canadian health authorities. In addition, Doctors Without Borders, WHO and the Norwegian Institute of Public Health have invested considerable resources.

Dr Røttingen says the Ebola vaccine will most likely be licensed and available on the market at the earliest in 2016, once necessary approval procedures have been carried out. Recommendations on use are determined by the WHO Strategic Advisory Group of Experts (SAGE), and implementation is determined by the health authorities in each country. The vaccine will most likely be used in ring vaccination in future Ebola outbreaks.

Read about the trial results published in The Lancet.

(This article is primarily based on the Norwegian Institute of Public Health press release published on 31 July 2015.)


Related news

Latest news

Untrue rumours about an on-going incident at the Halden Research Reactor in Norway

The Norwegian Radiation Protection Authority has become aware that stories about an ongoing incident involving a “meltdown” at the Norwegian Institute for Energy Technology (IFE) reactor situated in Halden are currently ci...

Gulf Notified Body meeting in Manama Bahrain

At the end of January, the GSO (Gulf Standards Organization) arranged the first meeting with the present group of 23 Notified Bodies. These Notified Bodies are authorised by GSO to certify the electrical products as curren...


During the spring thaw period in Sweden, many small roads are closed to traffic despite the fact that they are fit for use. The BiFi research project has analysed the roads’ bearing capacity in real time using Internet-con...

Children with poor vitamin B12 status early in life struggle more with tasks, recognition and interpreting feelings

Small children with low levels of vitamin B12 had more difficulties solving cognitive tests, such as the ability to do puzzles, recognize letters and interpret other children’s feelings.

BP Awards Schlumberger Contract for Mad Dog 2 Project

Export Conference 2017: A changing world

Register for this year’s most important conference for Norwegian exporters. We can promise you an interesting and inspirational day!

Meet Elkem Silicon Materials at the Ceramics Expo 2017

Elkem Silicon Metrials invites to meet their team at the Ceramics Expo 2017. This is North America’s largest, free-to-attend exhibition for Ceramic manufacturing and applications.

Event - TechnipFMC at Gastech April 4

Multiple Indian languages on electronic products

The Indian Ministry of Electronics and Information Technology (MeitY) has approved guidelines issued by Bureau of Indian Standards (BIS) about the display of text in 22 Indian languages on certain electronic devices from 1...